MedTrace Logo

Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO

NCT07499037 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-02

No results posted yet for this study

Summary

The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.

Conditions

Interventions

DRUG

Low anticoagulation dose of argatroban and enoxaparin during ECMO

Study subjects in this group will receive low anticoagulation dose of argatroban and enoxaparin during ECMO

DRUG

Standard anticoagulation dose of argatroban and enoxaparin during ECMO

Study subjects in this group will receive standard anticoagulation dose of argatroban and enoxaparin during ECMO

Sponsors & Collaborators

  • University Hospital, Motol

    collaborator OTHER

  • University Hospital Ostrava

    lead OTHER

Principal Investigators

  • Filip Burša, MD,Ph.D.,EDEC · University Hospital Ostrava

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-31
Primary Completion
2029-09-30
Completion
2029-12-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07499037 on ClinicalTrials.gov